Increasing use of covalent and noncovalent inhibitors of Bruton's tyrosine kinase (BTK) has
elucidated a series of acquired drug-resistant BTK mutations in patients with B cell …

Targeted protein degradation (TPD) represents a revolutionary therapeutic strategy in
disease management, providing a stark contrast to traditional therapeutic approaches like …

E3 ligases, essential components of the ubiquitin-proteasome-mediated protein degradation
system, play a critical role in cellular regulation. By covalently attaching ubiquitin (Ub) …

Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, is an essential
effector of B-cell receptor (BCR) signaling. Chronic activation of BTK-mediated BCR …

Target protein degradation (TPD) has emerged as a revolutionary approach in drug
discovery, leveraging the cell's intrinsic machinery to selectively degrade disease …

BACKGROUND: Doxorubicin is an effective chemotherapeutic agent, but its use is limited by
acute and chronic cardiotoxicity. Exercise training has been shown to protect against …

The PI3K signaling pathway regulates key cellular processes and is one of the most
aberrantly activated pathways in cancer. The class I PI3K catalytic subunits p110γ and …

Bruton's tyrosine kinase (BTK) is an attractive target in inflammatory and autoimmune
diseases. However, the effectiveness of BTK inhibitors is limited by side effects and drug …

Although the chronic lymphocytic leukemia (CLL) treatment landscape has changed
dramatically, unmet clinical needs are emerging, as CLL in many patients does not respond …

Bruton tyrosine kinase (BTK) belongs to the TEC family of nonreceptor kinases and is
expressed in various hematopoietic cells, including B cells, myeloid cells, and platelets (1) …